uniQure
NEWS
Companies from across Europe, Asia and around the globe share pipeline and business updates.
A report about Amsterdam-based uniQure indicated it is looking at various options, including a potential sale. As a result, company stock jumped as much as 10% in premarket trading.
April 17, 2019 is the 29th World Hemophilia Day, a designated day to create awareness of the disease. Hemophilia is one of a number of bleeding disorders. The blood of people with hemophilia does not clot normally as the result of insufficient clotting factor. As a result, they can bleed for a longer time.
Based in Lexington, Mass. and Amsterdam, The Netherlands, uniQure updated its Phase IIb trial of AMT-061 in hemophilia B. AMT-061 is an AAV5-based gene therapy that contains a FIX-Padua variant, meaning a patent-protected form of Factor IX, the missing or insufficient protein that results in the disease.
Across the globe, pharma companies are making an impact. Last week BioSpace launched the first of a weekly roundup of international biotech and pharma news. Here’s the latest edition.
As the European Medicines Agency prepares to make Amsterdam its new home following the U.K.’s Brexit, Holland is likely to see its biopharma industry snag a hoped-for boost in new business due to the presence of the regulatory agency.
It feels like we’re standing on the edge of a precipice. Despite the ho-hum recent performance of biotech stocks, amazing things are about to happen. And one of the most amazing of all is gene therapy.
Hemophilia B patients have some good news to cheer. Data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of patients. However, uniQure wasn’t the only company touting positive news in the treatment of hemophilia.
During the 2016 U.S. presidential election, the push for lower drug prices became one of the hot-button topics. Now there appears to be some efforts by advocacy groups and government entities to tackle the subject in several different ways.
JOBS
IN THE PRESS